Holen Sie sich die Stockscreener-App
3.44
2.99%
0.10
Handel nachbörslich:
3.44
Schlusskurs vom Vortag:
$3.34
Offen:
$3.34
24-Stunden-Volumen:
1.56M
Relative Volume:
1.54
Marktkapitalisierung:
$435.71M
Einnahmen:
$193.01M
Nettoeinkommen (Verlust:
$-12.15M
KGV:
-38.22
EPS:
-0.09
Netto-Cashflow:
$454.00K
1W Leistung:
+24.19%
1M Leistung:
-6.52%
6M Leistung:
-46.83%
1J Leistung:
-42.38%
1-Tages-Spanne:
$3.33
$3.47
1-Wochen-Bereich:
$2.6209
$3.53
52-Wochen-Spanne:
$2.37
$7.63
Cytek Biosciences Inc Stock (CTKB) Company Profile
Firmenname
Cytek Biosciences Inc
Sektor
Branche
Telefon
(877) 922-9835
Adresse
47215 LAKEVIEW BOULEVARD, FREMONT
Vergleichen Sie CTKB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
3.44 | 328.05M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
133.58 | 231.14B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.89 | 146.12B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.44 | 105.64B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.60B | 5.54B | 4.18B | 623.10M | 7.00 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-09 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-31 | Herabstufung | Goldman | Buy → Sell |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-07-19 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
Cytek Biosciences Inc Aktie (CTKB) Neueste Nachrichten
Bank of America Corp DE Boosts Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences Leads Our Top 3 Penny Stock Selections - Yahoo Finance
ProShare Advisors LLC Has $235,000 Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Jane Street Group LLC - Defense World
Ameriprise Financial Inc. Has $1.62 Million Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System - MSN
Optimizing Lab Efficiency with Cytek's Aurora Evo Flow Cytometer - Lab Manager
The Market Doesn't Like What It Sees From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Yet As Shares Tumble 31% - simplywall.st
Where are the Opportunities in (CTKB) - news.stocktradersdaily.com
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer - SINA HONG KONG LIMITED
Cytek® Biosciences Is Setting the New Standard for Full - GlobeNewswire
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer - GlobeNewswire Inc.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Millennium Management LLC - Defense World
Deutsche Bank AG Acquires 36,542 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Given New $7.00 Price Target at Morgan Stanley - Defense World
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Cytek Management Sets Key Investor Presentation at Goldman Sachs Healthcare Conference - Stock Titan
Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock - Benzinga
Cytek Biosciences (CTKB) Price Target Reduced by Morgan Stanley - GuruFocus
Cytek Biosciences (CTKB) Price Target Reduced by Morgan Stanley | CTKB Stock News - GuruFocus
Cytek Biosciences (CTKB) Price Target Revised by Morgan Stanley - GuruFocus
Cytek Biosciences (CTKB) Price Target Revised by Morgan Stanley | CTKB Stock News - GuruFocus
Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Institutional investors may adopt severe steps after Cytek Biosciences, Inc.'s (NASDAQ:CTKB) latest 10% drop adds to a year losses - simplywall.st
Cytek Biosciences stock hits 52-week low at $2.5 amid market challenges - Investing.com Canada
BNP Paribas Financial Markets Takes Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
(CTKB) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stake Raised by Northern Trust Corp - Defense World
Cytek Biosciences (CTKB) Faces Price Target Cut Amid Weak Market Dynamics | CTKB Stock News - GuruFocus
Price T Rowe Associates Inc. MD Boosts Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Goldman Sachs Maintains 'Sell' Rating on Cytek Biosciences (CTKB - GuruFocus
Cytek Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2025 Earnings Call Transcript - Insider Monkey
Dimensional Fund Advisors LP Grows Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (CTKB) Downgraded to Hold as Challenges Persis - GuruFocus
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates - MSN
Cytek Biosciences: Earnings Call Reveals Mixed Fortunes - TipRanks
Cytek Biosciences stock rating cut, price target drops to $4 By Investing.com - Investing.com Nigeria
Cytek Biosciences stock rating cut, price target drops to $4 - Investing.com
TD Cowen Downgrades Cytek Biosciences to Hold From Buy, Adjusts Price Target to $4 From $7 - marketscreener.com
Cytek Biosciences (CTKB) Downgraded to Hold as Challenges Persist | CTKB Stock News - GuruFocus
Cytek Biosciences Faces Revenue Challenges and Market Uncertainty, Downgraded to Hold - TipRanks
Cytek Biosciences Inc (CTKB) Q1 2025 Earnings Call Highlights: Navigating Growth Amid Market ... By GuruFocus - Investing.com Canada
Cytek Biosciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Cytek Biosciences Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Cytek Biosciences misses Q1 2025 earnings forecasts - Investing.com
Cytek Biosciences, Inc. SEC 10-Q Report - TradingView
Cytek Biosciences (CTKB) Reports Q1 Revenue Below Expectations | CTKB Stock News - GuruFocus
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.56%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):